The Pathology of Hereditary Breast Cancer

Hereditary Cancer in Clinical Practice

Volumn 2, Issue 3, 2004, Pages

  Honrado, Emiliano ^a   Benítez, Javier ^a   Palacios, José ^a  

^a Structural Biology and Biocomputing Programme   (Spain)

Author keywords

BRCA1; BRCA2; histopathology; non BRCA1 2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; KERATIN; P CADHERIN; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; BREAST CARCINOMA; CONTROLLED STUDY; DIAGNOSIS; GERMLINE MUTATION; HEREDITARY BREAST CANCER; HISTOPATHOLOGY; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INVASIVE DUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MEDULLARY CARCINOMA; MITOSIS; NEOPLASTIC CELL TRANSFORMATION; PHENOTYPE; PROLIFERATION INDEX; REVIEW; SURGERY; TUBULOGENESIS;

EID: 85086843977     PISSN: 17312302     EISSN: 18974287     Source Type: Journal    
DOI: 10.1186/1897-4287-2-3-131     Document Type: Review

References (70)

1. Y. Miki J. Swensen D. Shattuck-Eidens P.A. Futreal K. Harshman S. Tavtigian Q. Liu C. Cochran L.M. Bennett W. Ding R. Bell J. Rosenthal C. Hussey T. Trant M. Mc Clure C. Frye T. Hattier R. Phelps A. Haugen-Strano H. Katcher K. Yakumo Z. Gholami D. Saffer S. Stone S. Bayer C. Wray R. Bogden P. Dayananth J. Ward P. Tonin S. Narod P.K. Bristow F.H. Norris L. Helvering P. Morrison P. Rosteck M. Lai J.C. Barret C. Lewis S. Neuhausen L.A. Cannon-Albrigh D. Goldgar R. Wiseman A. Kamb M.H. Skolnick A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 Science 1994 266 66 71 10.1126/science.7545954 1:CAS:528:DyaK2MXhtF2ns70%3D 7545954
2. R. Wooster G. Bignell J. Lancaster S. Swift S. Seal J. Mangion N. Collins S. Gregory C. Gumbs G. Micklem Identification of the breast cancer susceptibility gene BRCA2 Nature 1995 378 789 792 10.1038/378789a0 1:CAS:528:DyaK28XltFWi 8524414
3. Easton DF, Bishop DT, Ford D, Crockford GP: Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium.Am J Hum Genet52: 678–701.
4. M.R. Stratton D. Ford S. Neuhasen S. Seal R. Wooster L.S. Friedman M.C. King V. Egilsson P. Devilee R. McManus P.A. Daly E. Smyth B.A. Ponder J. Peto L.A. Cannon-Albright D.F. Easton D.E. Goldgar Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q Nat Genet 1994 7 103 107 10.1038/ng0594-103 1:CAS:528:DyaK2cXktlaitbY%3D 8075631
5. C.I. Szabo M.C. King Population genetics of BRCA1 and BRCA2 Am J Hum Genet 1997 60 1013 1020 1712447 1:STN:280:DyaK2s3psVeqsA%3D%3D 9150148
6. D. Ford D.F. Easton M. Stratton S. Narod D. Goldgar P. Devilee D.T. Bishop B. Weber G. Lenoir J. Chang-Claude H. Sobol M.D. Teare J. Struewing A. Arason S. Scherneck J. Peto T.R. Rebbeck P. Tonin S. Neuhausen R. Barkardottir J. Eyfjord H. Lynch B.A. Ponder S.A. Gayther J.M. Birch A. Lindblom D. Stoppa-Lyonnet Y. Bignon A. Borg U. Hamann N. Haites R.J. Scott C.M. Maugard H. Vasen S. Seitz L.A. Cannon-Albright A. Schofield M. Zelada-Hedman the Breast Cancer Linkage Consortium Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families Am J Hum Genet 1998 62 676 689 1376944 10.1086/301749 1:CAS:528:DyaK1MXlvFeh 9497246
7. H.A. Shih F.J. Couch K.L. Nathanson M.A. Blackwood T.R. Rebbeck K.A. Armstrong K. Calzone J. Stopfer S. Seal M.R. Stratton B.L. Weber BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic J Clin Oncol 2002 20 994 999 10.1200/JCO.20.4.994 1:CAS:528:DC%2BD38XitFOqtbc%3D 11844822
8. A. Osorio A. Barroso B. Martinez A. Cebrian J.M. San Roman F. Lobo M. Robledo J. Benitez Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families Br J Cancer 2000 82 1266 1270 2374482 10.1054/bjoc.1999.1089 1:CAS:528:DC%2BD3cXisFOntb8%3D 10755399
9. M. de la Hoya A. Osorio J. Godino S. Sulleiro A. Tosar P. Perez-Segura C. Fernandez R. Rodriguez E. Diaz-Rubio J. Benitez P. Devilee T. Caldes Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing Int J Cancer 2002 97 466 471 10.1002/ijc.1627 1:CAS:528:DC%2BD38XkvFegsw%3D%3D 11802208
10. S.R. Lakhani M.D. Vijver MJVan De J. Jacquemier T.J. Anderson P.P. Osin L. McGuffog D.F. Easton The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2 J Clin Oncol 2002 20 2310 2318 10.1200/JCO.2002.09.023 1:CAS:528:DC%2BD38XktVKrs7o%3D 11981002
11. S.R. Lakhani J. Jacquemier J.P. Sloane B.A. Gusterson T.J. Anderson M.D. Vijver MJvan de L.M. Farid D. Venter A. Antoniou A. Storfer-Isser E. Smyth C.M. Steel N. Haites R.J. Scott D. Goldgar S. Neuhausen P.A. Daly W. Ormiston R. McManus S. Scherneck B.A. Ponder D. Ford J. Peto D. Stoppa-Lyonnet Y.J. Bignon J.P. Struewing N.K. Spurr D.T. Bishop J.G. Klijn P. Devilee C.J. Cornelisse C. Lasset G. Lenoir R.B. Barkardottir V. Egilsson U. Hamann J. Chang-Claude H. Sobol B. Weber M.R. Stratton D.F. Easton Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations J Natl Cancer Inst 1998 90 1138 1145 10.1093/jnci/90.15.1138 1:CAS:528:DyaK1cXlsVOrs78%3D 9701363
12. S.R. Lakhani D.F. Easton M.R. Stratton T. Consortium tBCL Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases Breast Cancer Linkage Consortium. Lancet 1997 349 1505 1510
13. J.E. Armes A.J. Egan M.C. Southey G.S. Dite M.R. McCredie G.G. Giles J.L. Hopper D.J. Venter The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study Cancer 1998 83 2335 2345 10.1002/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.0.CO;2-N 1:STN:280:DyaK1M%2FlsValug%3D%3D 9840533
14. S.R. Lakhani The pathology of familial breast cancer: morphological aspects Breast Cancer Res 1999 1 31 35 138498 10.1186/bcr10 1:STN:280:DC%2BD3MzlsVGnsw%3D%3D 11250680
15. K.A. Phillips Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers J Clin Oncol 2000 18 107S 112S 1:CAS:528:DC%2BD3cXot1antLo%3D 11060337
16. W.D. Foulkes I.M. Stefansson P.O. Chappuis L.R. Begin J.R. Goffin N. Wong M. Trudel L.A. Akslen Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer J Natl Cancer Inst 2003 95 1482 1485 10.1093/jnci/djg050 1:CAS:528:DC%2BD3sXnvVCjtrk%3D 14519755
17. W.D. Foulkes J.S. Brunet I.M. Stefansson O. Straume P.O. Chappuis L.R. Begin N. Hamel J.R. Goffin N. Wong M. Trudel L. Kapusta P. Porter L.A. Akslen The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+phenotype of BRCA1-related breast cancer Cancer Res 2004 64 830 835 10.1158/0008-5472.CAN-03-2970 1:CAS:528:DC%2BD2cXhtFCgtLo%3D 14871808
18. W.D. Foulkes K. Metcalfe P. Sun W.M. Hanna H.T. Lynch P. Ghadirian N. Tung O.I. Olopade B.L. Weber J. McLennan I.A. Olivotto L.R. Begin S.A. Narod Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type Clin Cancer Res 2004 10 2029 2034 10.1158/1078-0432.CCR-03-1061 1:CAS:528:DC%2BD2cXisVGlu7c%3D 15041722
19. R.L. Ridolfi P.P. Rosen A. Port D. Kinne V. Mike Medullary carcinoma of the breast: a clinicopathologic study with 10-year follow-up Cancer 1977 40 1365 1385 10.1002/1097-0142(197710)40:4<1365::AID-CNCR2820400402>3.0.CO;2-N 1:STN:280:DyaE1c%2FgtFKhsQ%3D%3D 907958
20. J.R. Rubens K.B. Lewandrowski D.B. Kopans F.C. Koerner D.A. Hall K.A. McCarthy Medullary carcinoma of the breast. Overdiagnosis of a prognostically favorable neoplasm Arch Surg 1990 125 601 604 10.1001/archsurg.1990.01410170047010 1:STN:280:DyaK3c3jtl2gug%3D%3D 2331218
21. V. Rapin G. Contesso H. Mouriesse F. Bertin M.J. Lacombe J.D. Piekarski J.P. Travagli C. Gadenne S. Friedman Medullary breast carcinoma. A reevaluation of 95 cases of breast cancer with inflammatory stroma Cancer 1988 61 2503 2510 10.1002/1097-0142(19880615)61:12<2503::AID-CNCR2820611219>3.0.CO;2-3 1:STN:280:DyaL1c3htVagsQ%3D%3D 2835145
22. P.O. Chappuis V. Nethercot W.D. Foulkes Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer Semin Surg Oncol 2000 18 287 295 10.1002/(SICI)1098-2388(200006)18:4<287::AID-SSU3>3.0.CO;2-5 1:STN:280:DC%2BD3c3ms1CksQ%3D%3D 10805950
23. J.N. Marcus P. Watson D.L. Page S.A. Narod G.M. Lenoir P. Tonin L. Linder-Stephenson G. Salerno T.A. Conway H.T. Lynch Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage Cancer 1996 77 697 709 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W 1:STN:280:DyaK287os1ymtg%3D%3D 8616762
24. J.N. Marcus P. Watson D.L. Page S.A. Narod P. Tonin G.M. Lenoir O. Serova H.T. Lynch BRCA2 hereditary breast cancer pathophenotype Breast Cancer Res Treat 1997 44 275 277 10.1023/A:1005830230664 1:STN:280:DyaK2svhtFSrtA%3D%3D 9266108
25. B.A. Agnarsson J.G. Jonasson I.B. Bjornsdottir R.B. Barkardottir V. Egilsson H. Sigurdsson Inherited BRCA2 mutation associated with high grade breast cancer Breast Cancer Res Treat 1998 47 121 127 10.1023/A:1005853022804 1:CAS:528:DyaK1cXhtlKqsL8%3D 9497100
26. J.P. Garne K. Aspegren F. Linell F. Rank J. Ranstam Primary prognostic factors in invasive breast cancer with special reference to ductal carcinoma and histologic malignancy grade Cancer 1994 73 1438 1448 10.1002/1097-0142(19940301)73:5<1438::AID-CNCR2820730519>3.0.CO;2-Y 1:STN:280:DyaK2c7lsFWhtg%3D%3D 8111711
27. D.E. Henson L. Ries L.S. Freedman M. Carriaga Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index Cancer 1991 68 2142 2149 10.1002/1097-0142(19911115)68:10<2142::AID-CNCR2820681010>3.0.CO;2-D 1:STN:280:DyaK38%2FgsFWltw%3D%3D 1913453
28. J. Palacios E. Honrado A. Osorio A. Cazorla D. Sarrio A. Barroso S. Rodriguez J.C. Cigudosa O. Diez C. Alonso E. Lerma L. Sanchez C. Rivas J. Benitez Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers Clin Cancer Res 2003 9 3606 3614 1:CAS:528:DC%2BD3sXosVOlurc%3D 14506147
29. B.J. Lynch J.A. Holden S.S. Buys S.L. Neuhausen D.K. Gaffney Pathobiologic characteristics of hereditary breast cancer Hum Pathol 1998 29 1140 1144 10.1016/S0046-8177(98)90427-0 1:STN:280:DyaK1cvlt12itw%3D%3D 9781655
30. R. Clarke M.C. Liu K.B. Bouker Z. Gu R.Y. Lee Y. Zhu T.C. Skaar B. Gomez K. O'Brien Y. Wang L.A. Hilakivi-Clarke Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling Oncogene 2003 22 7316 7339 10.1038/sj.onc.1206937 1:CAS:528:DC%2BD3sXotlajurw%3D 14576841
31. J.E. Armes L. Trute D. White M.C. Southey F. Hammet A. Tesoriero A.M. Hutchins G.S. Dite M.R. McCredie G.G. Giles J.L. Hopper D.J. Venter Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study Cancer Res 1999 59 2011 2017 1:CAS:528:DyaK1MXislejtL4%3D 10213514
32. M.E. Robson P.O. Chappuis J. Satagopan N. Wong J. Boyd J.R. Goffin C. Hudis D. Roberge L. Norton L.R. Begin K. Offit W.D. Foulkes A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment Breast Cancer Res 2004 6 R8 R17 314444 10.1186/bcr658 1:CAS:528:DC%2BD2cXnsl2hsw%3D%3D 14680495
33. P. Osin B.A. Gusterson E. Philp J. Waller J. Bartek J. Peto T. Crook Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers Eur J Cancer 1998 34 1683 1686 10.1016/S0959-8049(98)00248-2 1:CAS:528:DyaK1cXntlShtbg%3D 9893652
34. P.P. Osin S.R. Lakhani The pathology of familial breast cancer: immunohistochemistry and molecular analysis Breast Cancer Res 1999 1 36 40 138499 10.1186/bcr11 1:CAS:528:DC%2BD3cXlsFKgsbw%3D 11250681
35. J. Hurlimann B. Larrinaga D.L. Vala bcl-2 protein in invasive ductal breast carcinomas Virchows Arch 1995 426 163 168 10.1007/BF00192638 1:STN:280:DyaK2M3ns12mtQ%3D%3D 7757287
36. S. Baccouche J. Daoud M. Frikha R. Mokdad-Gargouri A. Gargouri R. Jlidi Immunohistochemical status of p53, MDM2, bcl2, bax, and ER in invasive ductal breast carcinoma in Tunisian patients Ann N Y Acad Sci 2003 1010 752 763 10.1196/annals.1299.136 1:CAS:528:DC%2BD2cXisFeqtrs%3D 15033823
37. H. Joensuu L. Pylkkanen S. Toikkanen Bcl-2 protein expression and long-term survival in breast cancer Am J Pathol 1994 145 1191 1198 1887415 1:STN:280:DyaK2M%2FmvValtw%3D%3D 7977649
38. P. Freneaux D. Stoppa-Lyonnet E. Mouret M. Kambouchner A. Nicolas B. Zafrani A. Vincent-Salomon A. Fourquet H. Magdelenat X. Sastre-Garau Low expression of bcl-2 in Brca1-associated breast cancers Br J Cancer 2000 83 1318 1322 2408784 10.1054/bjoc.2000.1438 1:CAS:528:DC%2BD3cXos12hu7g%3D 11044356
39. H.F. Frierson Jr M.J. Gaffey L.R. Zukerberg A. Arnold M.E. Williams Immunohistochemical detection and gene amplification of cyclin D1 in mammary infiltrating ductal carcinoma Mod Pathol 1996 9 725 730 8832554
40. C.E. Gillett A.H. Lee R.R. Millis D.M. Barnes Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia J Pathol 1998 184 396 400 10.1002/(SICI)1096-9896(199804)184:4<396::AID-PATH1259>3.0.CO;2-G 1:CAS:528:DyaK1cXislagu78%3D 9664905
41. C. Gillett P. Smith W. Gregory M. Richards R. Millis G. Peters D. Barnes Cyclin D1 and prognosis in human breast cancer Int J Cancer 1996 69 92 99 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.0.CO;2-Q 1:STN:280:DyaK283gtFOitA%3D%3D 8608989
42. M. Loden M. Stighall N.H. Nielsen G. Roos S.O. Emdin H. Ostlund G. Landberg The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorigenesis based on pattern of genetic aberrations and inactivation of the pRb node Oncogene 2002 21 4680 4690 10.1038/sj.onc.1205578 1:CAS:528:DC%2BD38XltVShurY%3D 12096344
43. T. Crook L.A. Brooks S. Crossland P. Osin K.T. Barker J. Waller E. Philp P.D. Smith I. Yulug J. Peto G. Parker M.J. Allday M.R. Crompton B.A. Gusterson p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours Oncogene 1998 17 1681 1689 10.1038/sj.onc.1202106 1:CAS:528:DyaK1cXms1OnsL4%3D 9796697
44. K.A. Phillips K. Nichol H. Ozcelik J. Knight S.J. Done P.J. Goodwin I.L. Andrulis Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations J Natl Cancer Inst 1999 91 469 473 10.1093/jnci/91.5.469 1:CAS:528:DyaK1MXhvFKitLo%3D 10070948
45. J.R. Goffin P.O. Chappuis L.R. Begin N. Wong J.S. Brunet N. Hamel A.J. Paradis J. Boyd W.D. Foulkes Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data Cancer 2003 97 527 536 10.1002/cncr.11080 1:CAS:528:DC%2BD3sXhtlKhtbg%3D 12548593
46. M.S. Greenblatt P.O. Chappuis J.P. Bond N. Hamel W.D. Foulkes TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution Cancer Res 2001 61 4092 4097 1:CAS:528:DC%2BD3MXktVWqtrk%3D 11358831
47. J.S. Ross J.A. Fletcher HER-2/neu (c-erb-B2) gene and protein in breast cancer Am J Clin Pathol 1999 112 S53 67 1:CAS:528:DyaK1MXktlCjt7k%3D 10396301
48. G. Pauletti W. Godolphin M.F. Press D.J. Slamon Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization Oncogene 1996 13 63 72 1:CAS:528:DyaK28Xks1ens74%3D 8700555
49. O.P. Kallioniemi A. Kallioniemi W. Kurisu A. Thor L.C. Chen H.S. Smith F.M. Waldman D. Pinkel J.W. Gray ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization Proc Natl Acad Sci USA 1992 89 5321 5325 49283 10.1073/pnas.89.12.5321 1:CAS:528:DyaK38XksVGlt70%3D 1351679
50. H. Tsuda F. Akiyama H. Terasaki T. Hasegawa M. Kurosumi M. Shimadzu S. Yamamori G. Sakamoto Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression Cancer 2001 92 2965 2974 10.1002/1097-0142(20011215)92:12<2965::AID-CNCR10156>3.0.CO;2-A 1:CAS:528:DC%2BD38XjvVaqug%3D%3D 11753973
51. O.T. Johannsson I. Idvall C. Anderson A. Borg R.B. Barkardottir V. Egilsson H. Olsson Tumour biological features of BRCA1-induced breast and ovarian cancer Eur J Cancer 1997 33 362 371 10.1016/S0959-8049(97)89007-7 1:STN:280:DyaK2szgtVCqtQ%3D%3D 9155518
52. T.A. Grushko M.A. Blackwood P.L. Schumm F.G. Hagos M.O. Adeyanju M.D. Feldman M.O. Sanders B.L. Weber O.I. Olopade Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers Cancer Res 2002 62 1481 1488 1:CAS:528:DC%2BD38Xit1Khu78%3D 11888924
53. T. Sorlie R. Tibshirani J. Parker T. Hastie J.S. Marron A. Nobel S. Deng H. Johnsen R. Pesich S. Geisler J. Demeter C.M. Perou P.E. Lonning P.O. Brown A.L. Borresen-Dale D. Botstein Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 2003
54. T. Sorlie C.M. Perou R. Tibshirani T. Aas S. Geisler H. Johnsen T. Hastie M.B. Eisen M.D. Rijn Mvan de S.S. Jeffrey T. Thorsen H. Quist J.C. Matese P.O. Brown D. Botstein P. Eystein Lonning A.L. Borresen-Dale Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 2001 98 10869 10874 58566 10.1073/pnas.191367098 1:CAS:528:DC%2BD3MXntVGmsbo%3D 11553815
55. P.T. Simpson T. Gale J.S. Reis-Filho C. Jones S. Parry D. Steele A. Cossu M. Budroni G. Palmieri S.R. Lakhani Distribution and significance of 14-3-3sigma, a novel myoepithelial marker, in normal, benign, and malignant breast tissue J Pathol 2004 202 274 285 10.1002/path.1530 1:CAS:528:DC%2BD2cXislejsLg%3D 14991892
56. C. Jones A. Mackay A. Grigoriadis A. Cossu J.S. Reis-Filho L. Fulford T. Dexter S. Davies K. Bulmer E. Ford S. Parry M. Budroni G. Palmieri A.M. Neville M.J. O'Hare S.R. Lakhani Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer Cancer Res 2004 64 3037 3045 10.1158/0008-5472.CAN-03-2028 1:CAS:528:DC%2BD2cXjs1ehsbk%3D 15126339
57. A. Kovacs R.A. Walker P-cadherin as a marker in the differential diagnosis of breast lesions J Clin Pathol 2003 56 139 141 1769891 10.1136/jcp.56.2.139 1:STN:280:DC%2BD3s%2FltVWhsQ%3D%3D 12560394
58. G. Callagy E. Cattaneo Y. Daigo L. Happerfield L.G. Bobrow P.D. Pharoah C. Caldas Molecular classification of breast carcinomas using tissue microarrays Diagn Mol Pathol 2003 12 27 34 10.1097/00019606-200303000-00004 1:CAS:528:DC%2BD3sXntV2itLY%3D 12605033
59. M.D. Rijn Mvan de C.M. Perou R. Tibshirani P. Haas O. Kallioniemi J. Kononen J. Torhorst G. Sauter M. Zuber O.R. Kochli F. Mross H. Dieterich R. Seitz D. Ross D. Botstein P. Brown Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome Am J Pathol 2002 161 1991 1996 1850928 10.1016/S0002-9440(10)64476-8 12466114
60. J. Palacios E. Honrado A. Osorio O. Diez C. Rivas J. Benitez Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer J Natl Cancer Inst 2004 96 712 714 10.1093/jnci/djh115 15126609
61. L.J. van't Veer H. Dai M.D. Vijver MJvan de Y.D. He A.A. Hart M. Mao H.L. Peterse K.D. Kooy Kvan der M.J. Marton A.T. Witteveen G.J. Schreiber R.M. Kerkhoven C. Roberts P.S. Linsley R. Bernards S.H. Friend Gene expression profiling predicts clinical outcome of breast cancer Nature 2002 415 530 536 10.1038/415530a
62. Groep P, Bouter A, Zanden R, Menko FH, Buerger H, Verheijen RH, Wall E, van Diest PJ: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.
63. S.R. Lakhani B.A. Gusterson J. Jacquemier J.P. Sloane T.J. Anderson M.D. Vijver MJvan de D. Venter A. Freeman A. Antoniou L. McGuffog E. Smyth C.M. Steel N. Haites R.J. Scott D. Goldgar S. Neuhausen P.A. Daly W. Ormiston R. McManus S. Scherneck B.A. Ponder P.A. Futreal J. Peto D. Stoppa-Lyonnet Y.J. Bignon M.R. Stratton The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2 Clin Cancer Res 2000 6 782 789 1:STN:280:DC%2BD3c3gtlOnsw%3D%3D 10741697
64. N. Hoogerbrugge P. Bult L.M. de Widt-Levert L.V. Beex L.A. Kiemeney M.J. Ligtenberg L.F. Massuger C. Boetes P. Manders H.G. Brunner High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer J Clin Oncol 2003 21 41 45 10.1200/JCO.2003.02.137 1:STN:280:DC%2BD38jktF2jtA%3D%3D 12506168
65. N.D. Kauff E. Brogi L. Scheuer D.R. Pathak P.I. Borgen C.A. Hudis K. Offit M.E. Robson Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations Cancer 2003 97 1601 1608 10.1002/cncr.11225 12655515
66. C. Adem C. Reynolds C.L. Soderberg J.M. Slezak S.K. McDonnell T.J. Sebo D.J. Schaid J.L. Myers T.A. Sellers L.C. Hartmann R.B. Jenkins Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers Cancer 2003 97 1 11 10.1002/cncr.11048 12491499
67. M.C. King S. Wieand K. Hale M. Lee T. Walsh K. Owens J. Tait L. Ford B.K. Dunn J. Costantino L. Wickerham N. Wolmark B. Fisher Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial Jama 2001 286 2251 2256 10.1001/jama.286.18.2251 1:CAS:528:DC%2BD3MXosFCktr8%3D 11710890
68. R.B. Clarke A. Howell C.S. Potten E. Anderson Dissociation between steroid receptor expression and cell proliferation in the human breast Cancer Res 1997 57 4987 4991 1:CAS:528:DyaK2sXnsV2ktrY%3D 9371488
69. T.R. Rebbeck A.M. Levin A. Eisen C. Snyder P. Watson L. Cannon-Albright C. Isaacs O. Olopade J.E. Garber A.K. Godwin M.B. Daly S.A. Narod S.L. Neuhausen H.T. Lynch B.L. Weber Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers J Natl Cancer Inst 1999 91 1475 1479 10.1093/jnci/91.17.1475 1:STN:280:DyaK1MvgtVyisw%3D%3D 10469748
70. Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H: Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Hereditary Breast Cancer Clinical Study Group.Lancet356: 1876–1881. 10.1016/S0140-6736(00)03258-X